APF541Hu61 50μg
Active Leukocyte Cell Derived Chemotaxin 2 (LECT2)
Organism Species: *Homo sapiens* (Human)
Instruction manual

FOR RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

13th Edition (Revised in Aug, 2023)

[PROPERTIES]

Source: Eukaryotic expression.
Host: 293F cell
Residues: Gly19-Leu151
Tags: C-terminal His-tag
Purity: >95%
Endotoxin Level: <1.0EU per 1μg (determined by the LAL method).
Buffer Formulation: PBS, pH7.4, containing 5% Trehalose .
Original Concentration: 50μg/mL
Applications: Activity Assays.
(May be suitable for use in other assays to be determined by the end user.)
Predicted isoelectric point: 9.6
Predicted Molecular Mass: 16.2kDa
Accurate Molecular Mass: 16kDa as determined by SDS-PAGE reducing conditions.

[USAGE]

Reconstitute in ddH_2O to a concentration of 0.1-0.2 mg/mL. Do not vortex.

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.
Store at 2-8°C for one month.
Aliquot and store at -80°C for 12 months.
Stability Test: The thermal stability is described by the loss rate. The loss rate

was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

[SEQUENCE]

GP WANICAGKSS NEIRTCDRHG CGQYSAQRSQ
RPHQGVDILC SAGSTVYAPF TGMIVGQEKP YQNKNAINNG VRISGRGFCV
KMFYIKPIKY KGPIKKGEKL GTLLPLQKVY PGIQSHVHIE NCDSSDPTAY
L

[ACTIVITY]

Leukocyte Cell Derived Chemotaxin 2 (LECT2) is a secreted multifunctional cytokine mainly synthesized in the liver. It participates in immune regulation, inflammatory response and tissue remodelling by modulating leukocyte migration and activation. LECT2 takes part in pathological processes including liver fibrosis, metabolic disorders and tumour development. It mediates intercellular signal transduction and balances pro-inflammatory and anti-inflammatory effects under diverse physiological and pathological conditions. Abnormal LECT2 secretion disrupts tissue homeostasis and promotes the progression of chronic inflammatory lesions. LECT2 interacts with Lpa to affect lipid metabolism and inflammatory signalling cascades in circulation.Briefly, Lpa was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μL were then transferred to LECT2-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-Lpa pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630nm immediately. Measured by its binding ability in a functional ELISA. When recombinant human LECT2 is immobilized at 2 μg/mL(100 μL/well), the concentration of Lpa that produces 50% optimal binding-response is found to be approximately0.018 μg/mL.



Figure 1. The binding activity of recombinant human LECT2 and human Lpa

[IDENTIFICATION]



Figure 2. Gene Sequencing (extract)



Figure 3. SDS-PAGE

Sample: Active recombinant LECT2, Human

[IMPORTANT NOTE]

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.